Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

NCT06155279 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT06155279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06155279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 6, 2024
Completion date
March 31, 2027
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pleural mesothelioma